Another one! Peptide products drive 'hot' performance, Sanuo Biological's net profit for the first three quarters is expected to increase by 76%.
①Peptide active pharmaceutical ingredients and formulation products are selling well, driving Shen Nuo Biotech's net income in the first three quarters to reach as high as 61.1987 million yuan, with the highest year-on-year increase of 75.88%. ②In September of this year, Shen Nuo Biotech signed a GLP-1 peptide active pharmaceutical ingredient supply contract worth up to 0.35 billion yuan, with a performance period until December 31, 2025.
The first third-quarter forecast of the star board: Peptide active pharmaceutical ingredients 'hot selling', Nuotai biology's net profit increase reaches up to 181%.
①Nuote Bio is the first to release the performance forecast for the third quarter of 2024, benefiting from the sales growth of peptide active pharmaceutical ingredients, with an expected net income attributable to shareholders of 0.1 billion yuan to 0.14 billion yuan, a year-on-year increase of 100.56% to 180.78%. ②Nuote Bio is expanding its peptide workshop to meet the hot demand for GLP-1, expecting to further increase peptide production capacity by 10 tons per year by the first half of 2025.
What happened during the National Day holiday at home and abroad? Here is a summary of important financial news.
①Shanghai Stock Exchange: From October 8th, the acceptance time for designated trading order instructions will be extended; Goldman Sachs has raised the Chinese stock market to "overweight", expecting a further increase of 15-20%; ②Hong Kong stocks are booming with a high increase in the number of new brokerage accounts and margin trading data within the past week; Many places have introduced optimized policies for real estate, and the market has responded positively.
Another wave! The revised version of the "Biosecurity Act" introduced to the legislative agenda in the US Senate, but the suspense of "breaking through" still lingers.
①On the 23rd local time in the United States, the U.S. Senate will include Amendment S.3558 in the Senate legislative agenda by general order, confirming the new name of the bill, and there is unusual movement in the BrightGene system; ②Amendment S.3558 does not include the "grandfather clause" of the House version of the Biosecurity Act regarding exemptions, nor does it make any changes to the entities involved.
How will Sansure Biotech Inc.'s performance in the first half of the year be impacted by its respiratory products and its second curve strategy? | Earnings conference
①Sansure Biotech Inc. director Dai Lizhong revealed at the earnings conference that the respiratory product revenue for the first half of 2024 is basically on par with the total for the entire previous year. ②The sales of respiratory products exceeded 0.4 billion yuan last year, and the overall revenue for the first half of this year is approximately 0.72 billion yuan. Based on this calculation, the proportion of respiratory product revenue is about 56%.
Listed companies have carried out intensive buybacks this week! Wuxi Apptec has launched its third round of 'cancellation-style' buyback plan this year, with a maximum repurchase amount of 0.1 billion yuan. Here is a list of A-share repurchase names.
①This week, the A-share listed companies continue to buy back stocks. According to incomplete statistics from Caixin, 11 listed companies plan to repurchase up to 0.1 billion yuan (see table); ②wuxi apptec, following the completion of the first two repurchase plans on February 5 and May 22, announced another 1 billion yuan repurchase plan on Tuesday evening. After the repurchase is completed, all repurchased shares will be cancelled and the registered capital will be reduced.